Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey
ICON plc (NASDAQ: ICLR), a leading clinical research organization, has released a survey of 120+ biotech and pharma professionals focusing on neurodegenerative disorder treatments. Despite recent successes in Alzheimer's disease treatments, challenges in neurodegenerative trials persist. ICON's new whitepaper, ‘Early, precise and efficient: The methods and technologies advancing Alzheimer’s and Parkinson’s R&D', highlights the potential of underutilized trial methodologies.
Biomarkers are important for early identification of trial participants. 97% of respondents use biomarkers, and 59% leverage AI for biomarker detection. However, biomarkers are not fully optimized, potentially making trials longer and costlier. Innovative trial designs are underused, with only 28% using adaptive designs, 22% using historic controls, and 19% utilizing master protocols.
Peter Schueler, MD, Senior VP at ICON, emphasizes the complexity of neurodegenerative research and the need for cost-effective and validated tools. Despite challenges, 87% of respondents plan diversified R&D investments, and AI is predominantly used in early development stages. Only 29% see collaboration as a key acceleration factor. Further industry engagement is essential to replicate and improve upon recent clinical successes.
ICON plc (NASDAQ: ICLR), una delle principali organizzazioni di ricerca clinica, ha pubblicato un sondaggio che coinvolge oltre 120 professionisti del settore biotech e farmaceutico, concentrandosi sui trattamenti per i disturbi neurodegenerativi. Nonostante i recenti successi nei trattamenti per la malattia di Alzheimer, continuano a persistere sfide nelle sperimentazioni neurodegenerative. Il nuovo whitepaper di ICON, ‘Precoce, preciso ed efficiente: I metodi e le tecnologie che avanzano R&D per Alzheimer e Parkinson', evidenzia il potenziale delle metodologie di trial sottoutilizzate.
I biomarcatori sono fondamentali per l'identificazione precoce dei partecipanti ai trial. Il 97% dei rispondenti utilizza biomarcatori e il 59% sfrutta l'IA per la loro rilevazione. Tuttavia, i biomarcatori non sono completamente ottimizzati, il che potrebbe rendere i trial più lunghi e costosi. I disegni sperimentali innovativi sono poco utilizzati, con solo il 28% che usa disegni adattivi, il 22% che utilizza controlli storici e il 19% che impiega protocolli master.
Peter Schueler, MD, Senior VP di ICON, sottolinea la complessità della ricerca neurodegenerativa e la necessità di strumenti validati e convenienti. Nonostante le sfide, l'87% dei rispondenti prevede investimenti diversificati in R&D e l'IA è principalmente utilizzata nelle fasi iniziali di sviluppo. Solo il 29% considera la collaborazione come un fattore chiave di accelerazione. Ulteriore coinvolgimento dell'industria è essenziale per replicare e migliorare i recenti successi clinici.
ICON plc (NASDAQ: ICLR), una de las principales organizaciones de investigación clínica, ha lanzado una encuesta con más de 120 profesionales de biotecnología y farmacéuticos centrándose en tratamientos para trastornos neurodegenerativos. A pesar de los recientes éxitos en los tratamientos para la enfermedad de Alzheimer, siguen persistiendo desafíos en los ensayos neurodegenerativos. El nuevo documento técnico de ICON, ‘Temprano, preciso y eficiente: Los métodos y tecnologías que avanzan la I+D en Alzheimer y Parkinson', destaca el potencial de metodologías de ensayo poco utilizadas.
Los biomarcadores son importantes para la identificación temprana de los participantes en los ensayos. El 97% de los encuestados utiliza biomarcadores, y el 59% aprovecha la IA para su detección. Sin embargo, los biomarcadores no están completamente optimizados, lo que podría hacer que los ensayos sean más largos y costosos. Los diseños de ensayos innovadores están subutilizados, con solo el 28% utilizando diseños adaptativos, el 22% utilizando controles históricos y el 19% utilizando protocolos maestros.
Peter Schueler, MD, Vicepresidente Senior de ICON, enfatiza la complejidad de la investigación neurodegenerativa y la necesidad de herramientas validadas y rentables. A pesar de los desafíos, el 87% de los encuestados planea inversiones diversificadas en I+D, y la IA se utiliza predominantemente en las primeras etapas de desarrollo. Solo el 29% ve la colaboración como un factor clave de aceleración. Un mayor compromiso de la industria es esencial para replicar y mejorar los recientes éxitos clínicos.
ICON plc (NASDAQ: ICLR)는 주요 임상 연구 조직으로서 신경 퇴행성 질환 치료에 초점을 맞춘 120명 이상의 생명공학 및 제약 전문가를 대상으로 한 조사를 발표했습니다. 알츠하이머병 치료의 최근 성공에도 불구하고 신경 퇴행성 시험에서는 여전히 도전과제가 존재합니다. ICON의 새로운 백서인 ‘조기, 정밀 및 효율적: 알츠하이머 및 파킨슨 병 연구 개발을 발전시키는 방법 및 기술’은 사용되지 않은 시험 방법론의 잠재력을 강조합니다.
바이오마커는 시험 참가자를 조기에 식별하는 데 중요합니다. 응답자의 97%가 바이오마커를 사용하며, 59%는 바이오마커 탐지에 AI를 활용하고 있습니다. 그러나 바이오마커는 완전히 최적화되어 있지 않아 시험이 더 길어지고 비용이 증가할 가능성이 있습니다. 혁신적인 시험 설계는 적게 사용되며, 28%만이 적응형 설계를 사용하고, 22%는 역사적 대조군을 사용하며, 19%는 마스터 프로토콜을 활용하고 있습니다.
ICON의 수석 부사장인 Peter Schueler MD는 신경 퇴행성 연구의 복잡성과 비용 효율적이고 검증된 도구의 필요성을 강조합니다. 도전 과제가 있음에도 불구하고 응답자의 87%는 다양화된 연구 개발 투자를 계획하고 있으며, AI는 주로 초기 개발 단계에서 사용됩니다. 협업을 주요 가속화 요소로 보는 사람은 29%에 불과합니다. 최근의 임상 성공을 복제하고 개선하기 위해서는 산업계의 추가 참여가 필수적입니다.
ICON plc (NASDAQ: ICLR), une organisation de recherche clinique de premier plan, a publié une enquête auprès de plus de 120 professionnels des biotechnologies et de l'industrie pharmaceutique axée sur les traitements des troubles neurodégénératifs. Malgré les succès récents dans les traitements de la maladie d'Alzheimer, des défis persistent lors des essais neurodégénératifs. Le nouveau document d'ICON, ‘Précoce, précis et efficace : Les méthodes et technologies qui améliorent la R&D sur Alzheimer et Parkinson', met en avant le potentiel des méthodologies de tests sous-utilisées.
Les biomarqueurs sont importants pour l'identification précoce des participants aux essais. 97% des répondants utilisent des biomarqueurs, et 59% tirent parti de l'IA pour leur détection. Cependant, les biomarqueurs ne sont pas entièrement optimisés, ce qui pourrait allonger et rendre les essais plus coûteux. Les conceptions d'essais innovants sont sous-utilisées, avec seulement 28% utilisant des conceptions adaptatives, 22% utilisant des contrôles historiques et 19% utilisant des protocoles maîtres.
Peter Schueler, MD, vice-président senior chez ICON, souligne la complexité de la recherche neurodégénérative et le besoin d'outils validés et rentables. Malgré les défis, 87% des répondants prévoient des investissements diversifiés en R&D, et l'IA est principalement utilisée dans les premières phases de développement. Seuls 29% considèrent que la collaboration est un facteur clé d'accélération. Un engagement accru de l'industrie est essentiel pour reproduire et améliorer les récents succès cliniques.
ICON plc (NASDAQ: ICLR), eine führende Organisation für klinische Forschung, hat eine Umfrage unter über 120 Fachleuten aus der Biotech- und Pharmaindustrie veröffentlicht, die sich auf Behandlungen für neurodegenerative Erkrankungen konzentriert. Trotz der jüngsten Erfolge bei der Behandlung von Alzheimer-Krankheiten gibt es weiterhin Herausforderungen bei neurodegenerativen Studien. ICONs neues Whitepaper mit dem Titel ‘Früh, präzise und effizient: Die Methoden und Technologien, die die Forschung und Entwicklung von Alzheimer und Parkinson vorantreiben', hebt das Potenzial untergenutzter Prüfmethoden hervor.
Biomarker sind wichtig für die frühzeitige Identifizierung von Studien Teilnehmern. 97% der Befragten verwenden Biomarker, und 59% setzen KI für die Erkennung von Biomarkern ein. Dennoch sind Biomarker nicht vollständig optimiert, was die Studien länger und kostspieliger machen kann. Innovative Studien design sind untergenutzt, wobei nur 28% adaptive Designs, 22% historische Kontrollen und 19% Master-Protokolle verwenden.
Peter Schueler, MD, Senior VP bei ICON, betont die Komplexität der neurodegenerativen Forschung und die Notwendigkeit kosteneffizienter und validierter Werkzeuge. Trotz der Herausforderungen planen 87% der Befragten diversifizierte F&E-Investitionen, wobei KI hauptsächlich in frühen Entwicklungsphasen eingesetzt wird. Nur 29% sehen Zusammenarbeit als einen wichtigen Beschleuniger. Ein verstärktes Engagement der Branche ist entscheidend, um kürzlich erreichte klinische Erfolge zu replizieren und zu verbessern.
- None.
- None.
ICON outlines how these innovations, including increased use of biomarkers and innovative trial designs, can be implemented in its new whitepaper: ‘Early, precise and efficient: The methods and technologies advancing Alzheimer’s and Parkinson’s R&D’.
Biomarkers are one of the most promising tools to identify potential clinical trial participants early in their disease progression. Encouragingly, nearly all respondents (
Innovative clinical trial methodologies can also speed up drug development, yet the survey findings indicate that respondents are not experimenting with these as much as they could. For example, only
Peter Schueler, MD, Senior Vice President, Drug Development Solutions, Neurosciences at ICON commented: “Neurodegenerative clinical research is exceptionally complex and challenging. The main two roadblocks survey respondents identified for innovative tools were costs and difficulty validating the impact. At ICON, we believe that the industry can make more use of lessons learned from recent successes in Alzheimer’s and continue to turn the tide in related indications such as Parkinson’s.”
Encouragingly, the survey revealed sponsors are not deterred from investing in R&D, especially in a diversified way. A large majority of respondents (
Interestingly, the survey findings suggest that collaboration across industry is also an underappreciated acceleration opportunity. Only
Peter Schueler observed: “The recent successes in developing treatments for Alzheimer's disease can be attributed, in part, to improvements in trial design and execution. Replicating and improving upon this initial clinical success is essential to alleviate the growing burden of neurodegenerative diseases. Further engagement is needed across the clinical trial ecosystem – with established platforms, advocacy groups, biotech and pharma – to examine how best to work together in a way that balances the practicalities and risks associated with this complex therapeutic research field.”
For further information on this whitepaper, please visit http://www.iconplc.com/CNS-trials
About ICON plc
ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in
ICON/ICLR-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20250108086626/en/
Media:
Claire Quinn, Corporate Communications, ICON
+353 87 4066091
claire.quinn@iconplc.com
Lisa Henry, Weber Shandwick (PR adviser)
+44 7785 458203
lhenry@webershandwick.com
Source: ICON plc
FAQ
What challenges do neurodegenerative clinical trials face according to the ICLR survey?
How are biomarkers being used in Alzheimer's clinical trials as per the ICLR survey?
What percentage of ICLR survey respondents use adaptive trial designs?
What innovative trial methodologies are underutilized according to the ICLR survey?
What investment trends are highlighted in the ICLR survey?
How is AI being used in neurodegenerative R&D according to the ICLR survey?
What does the ICLR survey suggest about industry collaboration in R&D?
